Therapy News: Voceryq™ Approval

The US Food and Drug Administration (FDA) has approved Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).